Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1589

Liver Fibrosis and Five Year Survival of Hepatocellular Cancer Cases Undergoing Transcatheter Arterial Chemo Embolization Using Small Doses  

Li, Hong (Department of Radiology, Renhe Hospital)
Hu, Yaohong (Three Gorges University)
Li, Na (Three Gorges University)
Zhou, Yan (Department of Radiology, Renhe Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1589-1593 More about this Journal
Abstract
Objective: To investigate liver fibrosis, TGF-${\beta}1$ levels and curative effects on hepatocellular carcinoma (HCC) with small and conventional dose perfusion chemotherapy by transcatheter arterial chemo embolization (TACE). Methods: Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super-selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups. Results: With conventional doses, four indices of liver fibrosis focusing on hyaluronate acide (HA), human procollagen type-III (hPC-III), collagen type-Ⅳ (Ⅳ-C) and transforming growth factor-${\beta}l$ (TGF-${\beta}1$) were obviously increased postoperative compared with preoperative (P<0.01); in contrast, with small doses there were no significant differences except for TGF-${\beta}1$. Five year survival demonstrated no significant differences between the two groups (P>0.05). Conclusion: To hepatocellular carcinoma patients treated by TACE, reducing doses of chemotherapy drugs can reduce progress of liver fibrosis, without impacting on five year survival.
Keywords
Hepatocellular carcinoma; transcatheter arterial chemoembolization; liver fibrosis; survival;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yan L (2002). Liver Surgery. Peking: The People's Medical Publishing House, 263-509.
2 Zhu S, Shan H, Huang M, et al (2000). The content changes of serum liver fibrosis indicators after transarterial chemoembolization for primary hepatic carcinoma and their clinical significance. J Clin Radiol, 19, 208-9.
3 Bruix J (1997). Treatment of hepatocellular carcinoma. Hepatology, 25, 259-62.   DOI   ScienceOn
4 Camma C, Schepis F, Orlando A, et al (2008). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology, 224, 47-54.
5 chen MS, Li JQ, Zhang YQ, et al (2002). High does iozedized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol, 8, 74.
6 Chen Y, Feng Y, Dai L, et al (2003). Screening and evaluation of non-traumatic diagnostic indexes to compensatory hepatic cirrhosis. Chinese Hapar Disease J, 11, 220-5.
7 Chung JW, Park JH, Han JK, et al (2007). Hepatic tumors: predisposing fators for complications of transeatheter oily chemoembolization. Radiology, 198, 33-40.
8 Chung JW, Park JH, Han JK, et al (1996). Hepatic tumors: predispo sing factors for complications of transcatheter oily chemoembolization. Radiology, 198, 33-40.   DOI
9 Feng G, Wu H, Xu L, et al (2002). The related to the fibrotic indicators of primary hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Chinese J of Hepatobiliary Surg, 8, 414-6.
10 Hu D, Li Z, Wang N, et al (2002). TACE treatment of Hepatic Carcinoma: A Comparative study of low dose versus conventional dose. Clin Radiol J, 23, 502-6.
11 Ikeda K, Kumada H, Saitoh S, et al (2001). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the cox proportional hazard model. Cancer, 68, 2150-4.
12 Lu W, Li Y, He X, et al (2004). A comparative study on the changes of serum fibrosis indicators after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. J Interv Radiol, 13, 247-9.
13 Kamada K, Nakanishi T, Kitamoto M, et al (2001). Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol, 12, 847-54.   DOI
14 Kamada K, Nakanishi T, Kitamato M, et al (2009). Long-term prognosis of patients undergoing transcatheter arterial chenmoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin liopiodol suspension and doxorubicin hydrocholoride emulsion. J Vasc Interv Radiol, 12, 843-7.
15 Li H, Hu D, Zhao Y, et al (2000). The relationship between curative effect of hepatic arterial chemoembolization and dose of Iodized Oil. China Hepatol J, 12, 235-6.
16 Lu W, Lu S (2006). Progress in diagnosis and treatment of liver fibrosis. Int J Digest Dis, 26, 13-6.
17 Xiao C, Zheng L, Jiang X, et al (1997). Observation of liver damage caused by hepatic arterial chemoembolization. China Radiol J, 31, 777-9.
18 Lu W, Li Y (2002). Hepatic carcinoma treated with trancatheter arterial chemoembolization. Clin Radiol J, 21, 735.
19 Lu W, Li Y, Li Z, et al (2003). A comparative study on necrosis and apoptosis of hepatocellular carcinoma cells after TACE with use of low-dose and conventional-dose anticancer drugs. Chinese J Radiol, 37, 232-7.
20 Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guide lines to evaluate the response to treatment in solidtumors. JNCI, 92, 205-16.   DOI   ScienceOn